scholarly journals PDPI VERSION OF COPD SCREENING QUESTIONNAIRE VALIDITY AS A SCREENING TOOLS

Respirology ◽  
2018 ◽  
Vol 23 ◽  
pp. 126-126
Keyword(s):  
Screening Tools ◽  
Screening Questionnaire ◽  
Questionnaire Validity

scholarly journals Psoriatic arthritis screening: a systematic review and meta-analysis

Rheumatology ◽  
2018 ◽  
Vol 58 (4) ◽  
pp. 692-707 ◽  
Author(s):  
Nicolas Iragorri ◽  
Glen Hazlewood ◽  
Braden Manns ◽  
Vishva Danthurebandara ◽  
Eldon Spackman
Keyword(s):  
Systematic Review ◽  
Psoriatic Arthritis ◽  
Sensitivity And Specificity ◽  
Screening Tool ◽  
Meta Analysis ◽  
Risk Of Bias ◽  
Screening Tools ◽  
Screening Questionnaire ◽  
Psa Screening ◽  
Early Psoriatic Arthritis

Abstract Objective To systematically review the accuracy and characteristics of different questionnaire-based PsA screening tools. Methods A systematic review of MEDLINE, Excerpta Medical Database, Cochrane Central Register of Controlled Trials and Web of Science was conducted to identify studies that evaluated the accuracy of self-administered PsA screening tools for patients with psoriasis. A bivariate meta-analysis was used to pool screening tool-specific accuracy estimates (sensitivity and specificity). Heterogeneity of the diagnostic odds ratio was evaluated through meta-regression. All full-text records were assessed for risk of bias with the QUADAS 2 tool. Results A total of 2280 references were identified and 130 records were assessed for full-text review, of which 42 were included for synthesis. Of these, 27 were included in quantitative syntheses. Of the records, 37% had an overall low risk of bias. Fourteen different screening tools and 104 separate accuracy estimates were identified. Pooled sensitivity and specificity estimates were calculated for the Psoriatic Arthritis Screening and Evaluation (cut-off = 44), Psoriatic Arthritis Screening and Evaluation (47), Toronto Psoriatic Arthritis Screening (8), Psoriasis Epidemiology Screening Tool (3) and Early Psoriatic Arthritis Screening Questionnaire (3). The Early Psoriatic Arthritis Screening Questionnaire reported the highest sensitivity and specificity (0.85 each). The I2 for the diagnostic odds ratios varied between 76 and 90.1%. Meta-regressions were conducted, in which the age, risk of bias for patient selection and the screening tool accounted for some of the observed heterogeneity. Conclusions Questionnaire-based tools have moderate accuracy to identify PsA among psoriasis patients. The Early Psoriatic Arthritis Screening Questionnaire appears to have slightly better accuracy compared with the Toronto Psoriatic Arthritis Screening, Psoriasis Epidemiology Screening Tool and Psoriatic Arthritis Screening and Evaluation. An economic evaluation could model the uncertainty and estimate the cost-effectiveness of PsA screening programs that use different tools.

scholarly journals Validation of the REM sleep behavior disorder screening questionnaire in the Czech population

2019 ◽  
Author(s):  
Jitka Bušková ◽  
Pavla Peřinová ◽  
Eva Miletínová ◽  
Petr Dušek ◽  
Evžen Růžička ◽  
...  
Keyword(s):  
Healthy Volunteers ◽  
Neurodegenerative Disorder ◽  
Rem Sleep Behavior Disorder ◽  
Behavior Disorder ◽  
Screening Tools ◽  
Validity And Reliability ◽  
Periodic Limb Movement Disorder ◽  
Sleep Behavior ◽  
Screening Questionnaire ◽  
Obstructive Sleep

Abstract Background Idiopathic rapid eye movement sleep behavior disorder (RBD) affects 1 – 2% of people over 60 years of age, and presents a high risk of developing a neurodegenerative disorder from the group of synucleinopathies, such as Parkinson’s disease, dementia with Lewy bodies and multiple system atrophy. Therefore, screening tools are needed. In 2007, the RBD screening questionnaire (RBD-SQ) was developed and has been translated into several languages. Aim of the study: The aim of study was to assess the validity and reliability of the Czech version of the RBD-SQ in a mixed population of sleep clinic patients, supplemented by healthy volunteers and RBD patients. Methods Participants included 81 RBD patients, 225 patients with other sleep disorders (obstructive sleep apnea, insomnia, restless legs syndrome and periodic limb movement disorder, other parasomnias, or central hypersomnias including narcolepsy) and 20 healthy volunteers. Results The mean RBD-SQ score in the RBD patients was 9.4 ± 2.8 points, and in the non-RBD group it was 4.5 ± 3.0 (P < 0.0001). Receiver -operator analysis yielded an area under the curve of 0.864, suggesting good diagnostic performance of the scale. When using a cut-off value for positivity of 5 points, sensitivity was 0.89 and specificity was 0.62. Conclusions The Czech version of the RBD-SQ is a sensitive tool for screening for RBD patients and helps to identify subjects for complete clinical workup.

scholarly journals Screening tool for malignant bowel obstruction in relapsed, metastatic ovarian cancer

ESMO Open ◽  
2019 ◽  
Vol 4 (2) ◽  
pp. e000463 ◽  
Author(s):  
Robert D Morgan ◽  
Sofia Stamatopoulou ◽  
Nerissa Mescallado ◽  
Geoff Saunders ◽  
Richard Welch ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Bowel Obstruction ◽  
Clinical Symptoms ◽  
Screening Tools ◽  
Control Group ◽  
Study Group ◽  
Malignant Bowel Obstruction ◽  
Screening Questionnaire ◽  
Improve Risk Stratification ◽  
Severity Scores

BackgroundMalignant bowel obstruction (MBO) is a common cause of morbidity and mortality in women diagnosed with ovarian cancer. Earlier detection of MBO may improve patient outcomes. There are currently no screening tools to assist detection.AimWe report a screening questionnaire that can be used to detect MBO, and how the severity score for key clinical symptoms correlate with radiological evidence of MBO from ovarian cancer.DesignA case–control study in which patients with relapsed, metastatic ovarian cancer were asked to answer 10 questions related to key clinical symptoms associated with intestinal obstruction. The study group included women with CT-confirmed MBO, whereas the control group had no evidence of MBO. Patients scored each question according to severity from 1 (least severe) to 5 (most severe).Setting/participantsBetween 1 June and 31 December 2016, 37 women completed the screening questionnaire.ResultsPatients in the study group (n=17) reported significantly higher (ie, more severe) scores for abdominal pain, nausea, vomiting and constipation. In contrast, differences in severity scores between groups did not differ significantly in response to questions regarding abdominal swelling, borborygmi, diarrhoea or loss of appetite. All patients in the study group more frequently stated that their symptoms had deteriorated within the 2 months prior to completing the questionnaire.ConclusionHere we report the key clinical symptoms associated with radiologically-confirmed MBO in relapsed, metastatic ovarian cancer. We recommend healthcare practitioners focus on these specific symptoms during patient consultations in order to improve risk stratification of MBO.

scholarly journals Validation of the REM sleep behavior disorder screening questionnaire in the Czech population

2019 ◽  
Author(s):  
Jitka Bušková ◽  
Pavla Peřinová ◽  
Eva Miletínová ◽  
Petr Dušek ◽  
Evžen Růžička ◽  
...  
Keyword(s):  
Healthy Volunteers ◽  
Eye Movement ◽  
Neurodegenerative Disorder ◽  
Behavior Disorder ◽  
Screening Tools ◽  
Rapid Eye Movement ◽  
Rapid Eye Movement Sleep ◽  
Sleep Behavior ◽  
Screening Questionnaire ◽  
Obstructive Sleep

Abstract Background: Idiopathic rapid eye movement sleep behavior disorder (iRBD) affects 1 – 2% of people over 60 years of age and presents a high risk of developing a neurodegenerative disorder from the group of synucleinopathies, such as Parkinson’s disease, dementia with Lewy bodies and multiple system atrophy. Therefore, screening tools are needed. In 2007, the rapid eye movement sleep behavior disorder screening questionnaire (RBD-SQ) was developed and has been translated into several languages. The aim of study was to assess the validity and reliability of the Czech version of the RBD-SQ in a mixed population of sleep clinic patients, supplemented by healthy volunteers and RBD patients. Methods: Participants included 81 iRBD patients, 205 patients with other sleep disorders (obstructive sleep apnea, insomnia, restless legs syndrome and periodic limb movement disorder, other parasomnias, or central hypersomnias including narcolepsy) and 20 healthy volunteers. ¨ Results: The mean RBD-SQ score in the iRBD patients was 9.4 ± 2.8 points, and in the non-RBD group it was 4.5 ± 3.0 (P < 0.0001). Receiver -operator analysis yielded an area under the curve of 0.864, suggesting good diagnostic performance of the scale. When using a cut-off value for positivity of 5 points, sensitivity was 0.89 and specificity was 0.62. Conclusions: The Czech version of the RBD-SQ is a sensitive tool for screening for iRBD patients and helps to identify subjects for complete clinical workup.

FRI0573 VALIDATION OF FOUR SCREENING TOOLS FOR PSORIATIC ARTHRITIS IN CHINESE PATIENTS WITH PSORIASIS: A MULTICENTER STUDY

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 889.1-889
Author(s):  
R. Cui ◽  
M. Chen ◽  
X. LI ◽  
X. L. Bi ◽  
Y. Ding ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
American Academy ◽  
Multicenter Study ◽  
Screening Tool ◽  
Screening Tools ◽  
Chinese Patients ◽  
Fast Method ◽  
Newly Diagnosed ◽  
Screening Questionnaire ◽  
New Instrument

Background:Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy affecting 6~30% of patients with skin or nail psoriasis. If PsA is not identified early and managed appropriately, progressive joint damage with deformities and disability may occur. Preliminary efforts to develop screening tools for the identification of PsA have met with variable success. Whether the tools function well or not in Chinese patients remains unknown.Objectives:We aimed to validate and compare the performance of 4 PsA screening tools in Chinese psoriasis patients.Methods:Consecutive psoriasis patients (dermatology cohort) attending dermatology clinics without previous diagnosis of inflammatory arthritis and consecutive newly diagnosed PsA patients (rheumatology cohort) attending rheumatology clinics were invited to complete the questionnaires: early arthritis for psoriatic patients (EARP), psoriatic arthritis screening and evaluation(PASE), psoriasis and arthritis screening questionnaire(PASQ), and psoriasis epidemiology screening tool (PEST). Receiver operating characteristic (ROC) curves were utilized to calculate diagnostic accuracy, least absolute shrinkage and selection operator(lasso) and binary logistic regressions to identify the most discriminative questions.Results:In this multicenter study, 379 patients in the dermatology cohort and 72 in the rheumatology cohort were recruited. In the dermatology cohort, 7.9% (30/379) were newly diagnosed with PsA. The EARP and PASQ tools demonstrated better discriminating ability for identifying PsA from psoriasis patients (yielded sensitivities/specificities were: 93.3%/92.3% and 90.0%/90.5%, while optimal cut-off values were: 3 and 5, respectively), and the good performance of EARP and PASQ was further confirmed in the rheumatology cohort. However, all these tools demonstrated low sensitivities (about 30%) with regard to screening the axial PsA. Based on the questions, a risk prediction model of PsA was established.Conclusion:The prevalence rate of undiagnosed PsA in the patients with psoriasis is 7.9%. Both EARP and PASQ tools show better favorable trade-off between sensitivity and specificity than PASE and PEST, while all the 4 tools are not sensitive to identify axial PsA.References:[1] Villani AP, Rouzaud M, Sevrain M, et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis.Journal of the American Academy of Dermatology2015;73(2): 242-8.[2] Tinazzi I, Adami S, Zanolin EM, et al. The early psoriatic arthritis screening questionnaire: a simple and fast method for the identification of arthritis in patients with psoriasis.Rheumatology (Oxford, England) 2012;51(11): 2058-63.[3] Majed Khraishi IL, Gerry Mugford. The Self-Administered Psoriasis and Arthritis Screening Questionnaire (PASQ): A Sensitive and Specific Tool for the Diagnosis of Early and Established Psoriatic Arthritis.Psoriasis Forum2010;16(2): 9-16.[4] Husni ME, Meyer KH, Cohen DS, Mody E, Qureshi AA. The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool.Journal of the American Academy of Dermatology2007;57(4): 581-7.[5] Ibrahim GH, Buch MH, Lawson C, Waxman R, Helliwell PS. Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire.Clinical and experimental rheumatology2009;27(3): 469-74.Acknowledgments:This project was supported by grants from National Natural Science Foundation of China (81771746 and 81471604).Disclosure of Interests:None declared

Construct validity and reliability of Finnish version of Örebro Musculoskeletal Pain Screening Questionnaire

2016 ◽  
Vol 13 (1) ◽  
pp. 148-153 ◽  
Author(s):  
Olli Ruokolainen ◽  
Marianne Haapea ◽  
Steven Linton ◽  
Katariina Korniloff ◽  
Arja Häkkinen ◽  
...  
Keyword(s):  
Health Care ◽  
Chronic Pain ◽  
Construct Validity ◽  
Musculoskeletal Pain ◽  
Internal Consistency ◽  
Intraclass Correlation ◽  
Screening Tools ◽  
Validity And Reliability ◽  
Hospital Visit ◽  
Screening Questionnaire

AbstractIntroductionChronic pain causes suffering for affected individuals and incurs costs to society through work disability. Interventions based on early screening of psychological risk factors for chronic pain using screening tools such as the Örebro Musculoskeletal Pain Screening Questionnaire (ÖMPSQ) have been found to reduce work absenteeism and health care visits and increase perceived health. The aim of the current study was to translate the ÖMPSQ into Finnish and test its validity and reliability in a patient sample.MethodsThe ÖMPSQ was forward–backward translated and cross-culturally adapted, and applied to our study population (n = 69), the members of which had been referred to the Department of Physical and Rehabilitation Medicine of Oulu University Hospital from primary health care centres in Northern Finland due to chronic low back pain. The patients answered the ÖMPSQ two weeks before the hospital visit, and the follow-up questionnaire either during the hospital visit, or after by mail. The reliability of the ÖMPSQ was evaluated using intraclass correlation coefficients (ICC). Factor analysis was used to group items of the ÖMPSQ, and internal consistency between the items was determined by calculating Cronbach’s alphas.ResultsThe cross-cultural adaptation revealed only minor semantic and cultural differences. Measurements showed reliability as moderate to nearly perfect for all of the ÖMPSQ items (ICC values ranged from 0.59 to 0.96). Items loaded into five different factors: disability, psychological symptoms, pain, fear avoidance, and work. All except one (work) showed acceptable internal consistency. The ÖMPSQ score was positively associated with both intensity of pain and the Oswestry Disability Index.Conclusions and implicationsThe reliability and construct validity of the Finnish version of the ÖMPSQ were good. The predictive ability of the ÖMPSQ in the Finnish population should be evaluated in further studies.

Toronto Psoriatic Arthritis Screening (ToPAS) Questionnaire: A Report from the GRAPPA 2009 Annual Meeting

2011 ◽  
Vol 38 (3) ◽  
pp. 546-547 ◽  
Author(s):  
VINOD CHANDRAN ◽  
DAFNA D. GLADMAN
Keyword(s):  
Psoriatic Arthritis ◽  
General Population ◽  
Annual Meeting ◽  
Screening Tools ◽  
Screening Questionnaire

The Toronto Psoriatic Arthritis Screening questionnaire (ToPAS) was developed as a tool to screen for psoriatic arthritis (PsA) in patients with psoriasis as well as in the general population. Thus, it differs from PsA-specific screening tools and may be used to screen for PsA in epidemiologic and family investigations. In a presentation at the 2009 annual meeting of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) in Stockholm, Sweden, the authors described the development, testing, and validation of the ToPAS tool. Results of a comparison of the ToPAS questionnaire with the Psoriatic Arthritis Screening and Evaluation (PASE) questionnaire were also presented. Modification and further validation of the ToPAS are under way.

Gute Verordnungspraxis bei älteren Patienten

2014 ◽  
Vol 71 (6) ◽  
pp. 366-373 ◽  
Author(s):  
Beate Wickop ◽  
Claudia Langebrake
Keyword(s):  
Ältere Patienten ◽  
Screening Tools ◽  
Unerwünschte Arzneimittelwirkungen ◽  
Leitliniengerechte Therapie

Patienten ab einem Alter von 65 Jahren sind die bedeutendste Zielgruppe der Pharmakotherapie. Die im Alter häufig auftretende Multimorbidität bedingt oft eine Polymedikation. Eine leitliniengerechte Therapie aller Erkrankungen ist problematisch und selten in Studien an älteren Patienten geprüft. Zudem sind im Alter auftretende pharmakokinetische und pharmakodynamische Veränderungen zu beachten. Diese bedingen, dass bestimmte Medikamente für ältere Patienten potentiell inadäquat sind, weil sie ein hohes Risiko für unerwünschte Arzneimittelwirkungen bergen. Zur Identifikation von potentiell inadäquater Medikation wurden mehrere Negativlisten und Screening-Tools entwickelt. Im Artikel werden die START/STOPP-Kriterien, die PRISCUS-Liste, die Österreichische PIM-Liste sowie die FORTA-Einteilung näher erläutert. Der Einsatz dieser Tools kann die Qualität der medikamentösen Therapie im Alter verbessern. Zudem empfiehlt sich ein regelmäßiger Medikationsreview. Die Bestimmung der im Alter meist eingeschränkten Nierenfunktion und eine entsprechende Dosisanpassung der Medikation sowie die Wahl einer niedrigen Einstiegsdosis beim Ansetzen eines neuen Medikamentes bei älteren Patienten können ebenfalls einen Beitrag zur Arzneimitteltherapiesicherheit leisten.

Sign in / Sign up

Export Citation Format

Share Document